Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context

Summary: Background: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing surveillance was conducted in India from 2020 to 2021 to gather real world safety data on Rabivax-S and Rabishield. Methods...

Full description

Bibliographic Details
Main Authors: Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Dhananjay Kapse, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:The Lancet Regional Health - Southeast Asia
Subjects:
Rabies vaccine
Rabies human monoclonal antibody
Safety
Post-marketing surveillance
Online Access:http://www.sciencedirect.com/science/article/pii/S2772368223000677

Internet

http://www.sciencedirect.com/science/article/pii/S2772368223000677

Similar Items